Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CELZ-201-DDT in Chronic Lower Back Pain with Degenerative Disc Disease
NCT06053242Phase 2Active, not recruiting
- Sponsor
- Creative Medical Technology Holdings, Inc.
- Start
- May 2024
- Primary completion
- Jan 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CELZ-201 in chronic low back pain (CLBP) and degenerative disc disease (DDD) (4 arms), sponsored by Creative Medical Technology Holdings, Inc. Primary endpoint: Safety and tolerability of CELZ-201-DDT at 6 months. Started May 2024; status: active, not recruiting.
02
Drugs
CELZ-201
03
Conditions
chronic low back pain (CLBP)degenerative disc disease (DDD)
Beyond the preview
Go deeper on NCT06053242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06053242.